PFG Advisors Has $2.65 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Posted by on Apr 11th, 2023

PFG Advisors increased its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 10.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,776 shares of the biopharmaceutical company’s stock after buying an additional 4,921 shares during the quarter. PFG Advisors’ holdings in Pfizer were worth $2,653,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of PFE. Assenagon Asset Management S.A. raised its position in Pfizer by 528.9% during the third quarter. Assenagon Asset Management S.A. now owns 12,401,164 shares of the biopharmaceutical company’s stock valued at $542,675,000 after acquiring an additional 10,429,412 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Pfizer by 13.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock worth $3,097,341,000 after buying an additional 6,972,650 shares during the period. Renaissance Technologies LLC acquired a new position in Pfizer in the 1st quarter valued at $311,238,000. Vanguard Group Inc. lifted its position in shares of Pfizer by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 493,584,761 shares of the biopharmaceutical company’s stock worth $21,599,270,000 after purchasing an additional 5,139,634 shares during the last quarter. Finally, First Trust Advisors LP raised its stake in Pfizer by 108.3% during the 1st quarter. First Trust Advisors LP now owns 7,909,665 shares of the biopharmaceutical company’s stock valued at $409,483,000 after purchasing an additional 4,112,528 shares during the last quarter. 67.62% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Pfizer

In related news, major shareholder Pfizer Inc bought 1,811,594 shares of the stock in a transaction that occurred on Friday, March 17th. The shares were acquired at an average price of $2.76 per share, with a total value of $4,999,999.44. Following the completion of the transaction, the insider now owns 5,952,263 shares in the company, valued at $16,428,245.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.05% of the stock is currently owned by insiders.

Pfizer Price Performance

Shares of PFE stock opened at $41.73 on Tuesday. The firm has a market capitalization of $235.54 billion, a price-to-earnings ratio of 7.61, a price-to-earnings-growth ratio of 1.40 and a beta of 0.64. Pfizer Inc. has a 12-month low of $39.23 and a 12-month high of $56.32. The company has a quick ratio of 1.00, a current ratio of 1.22 and a debt-to-equity ratio of 0.34. The firm has a fifty day moving average of $41.62 and a 200-day moving average of $45.45.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.11. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The company had revenue of $24.30 billion during the quarter, compared to the consensus estimate of $24.40 billion. During the same period in the prior year, the company earned $1.08 earnings per share. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 3.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. BMO Capital Markets reduced their price objective on Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a research report on Wednesday, February 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $75.00 price target on shares of Pfizer in a research note on Wednesday, February 1st. Barclays dropped their price objective on Pfizer from $49.00 to $44.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 1st. Jefferies Financial Group initiated coverage on shares of Pfizer in a report on Monday, March 6th. They issued a “hold” rating and a $43.00 target price on the stock. Finally, StockNews.com initiated coverage on shares of Pfizer in a research note on Thursday, March 16th. They issued a “buy” rating for the company. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $49.87.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Recommended Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.